JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

Ivarmacitinib, a novel Janus kinase 1 inhibitor, alleviates symptoms, reduces disease activity, and improves physical function and quality of life in patients with moderate to severe rheumatoid ...

Janus Kinase inhibitors (JAKis) are approved for the management of several chronic inflammatory diseases, from rheumatic conditions, to dermatological and ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

The aberrant immune response against self-antigens occurring in autoimmune diseases involves dysregulation of members of intracellular signal transduction pathways such as interleukin-2-inducible T ...